佩洛芬B是一种非毒素结合的微管稳定剂,具有前临床抗癌性质
Stephanie Vermeulen1,2, Sam Ernst1,3, Eva Blondeel1,2
1Laboratory of Experimental Cancer Research, Department of Human Structure and Repair, Ghent University, Ghent, Belgium.
Scientific reports
|December 5, 2024
概括
佩洛芬B (PPH) 是一种新的微管稳定剂,具有显著的抗癌活性. 它克服了帕克利塔克塞尔耐药性,并显示了附加效应,支持其临床研究.
科学领域:
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 像帕克利塔克塞尔 (PTX) 这样的毒素是第一线癌症疗法,可以稳定微管,但会引起副作用和耐药性.
- 微管的破坏对于细胞分裂和细胞恒温至关重要,导致细胞死亡.
- 佩洛芬B (PPH) 是一种佩洛鲁赛德A类比物,它与β-tubulin上的一处非毒素位点结合,以稳定微管.
研究的目的:
- 为了评估PPH在各种瘤类型中的抗癌疗效.
- 调查PPH的作用机制及其与帕克利塔塞尔的相互作用.
- 为了确定PPH是否可以克服PTX抵抗.
主要方法:
- 在已建立的细胞系,早期通道培养和ex vivo瘤衍生培养上测试PPH.
- 评估PPH对殖民地形成,细胞活力和细胞周期进展的影响.
- 分析PPH对突聚合促进蛋白 (TPPP) 和α-突乙化的影响.
主要成果:
- PPH显著抑制了殖民地形成,并降低了瘤细胞的活力.
- PPH与PTX表现出添加效应,并成功克服了PTX耐药性.
- PPH诱导了G2/M细胞循环停止,增加了TPPP,并促进了α-tubulin乙化.
结论:
- 在临床前模型中,PPH通过独特的微管结合机制表现出强大的抗癌活性.
- 由于PPH的非氧化物结合点相互作用,可以绕过PTX的添加性和耐药性.
- 作为一个有前途的抗癌治疗剂,PPH需要进一步的临床研究.
关键词:
乳腺癌是什么? 乳腺癌是什么微管稳定剂是一种微管稳定剂.卵巢癌是发生在卵巢中的癌症.帕克利塔克塞尔 (Paclitaxel) 是一种药物.佩洛芬二世 佩洛芬二世 佩洛芬二世这种类型的肉瘤是sarcoma.更多相关视频
08:13Spatiotemporal Subcellular Manipulation of the Microtubule Cytoskeleton in the Living Preimplantation Mouse Embryo using Photostatins
Published on: November 30, 2021
2.4K
15:53Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
Published on: August 21, 2013
14.9K
相关概念视频
01:15Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
01:10Drugs that Destabilize Microtubules
1.9K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K
01:45Destabilization of Microtubules
2.6K
The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
2.6K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:23Microtubule Formation
5.5K
Microtubules are dynamic structures that undergo continuous assembly and disassembly. They originate from specialized multi-protein complexes known as microtubule organizing centers or MTOCs. Within the MTOC, the point of origin of the microtubule is known as the minus end, while the end radiating outward is the plus end. Microtubules serve two primary functions — the organization of spindle complexes to separate sister chromatids during mitotic or meiotic cell division and the formation...
5.5K
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K